BALTIMORE – July 30, 2025 -- CDI Labs, a leading provider of services for proteome-wide antibody profiling and target identification, today announced the launch of its Pan-isotype Analysis Platform for serum antibody analysis services. The platform provides the unique capability to explicitly detect the binding of any antibody isotype or subclass to over eighty percent of the human proteome (using HuProt™) or to most vertebrate viruses (using VirScan®). Comprehensive analysis options include detection of pan-IgA (IgA1 and IgA2), IgA1, IgA2, IgD, IgE, pan-IgG (IgG1, IgG2, IgG3 and IgG4), IgG1, IgG2, IgG3, IgG4 and IgM.

The study of serum autoantibodies has traditionally focused on pan-IgG analysis where the IgG1, IgG2, IgG3 and IgG4 subclasses are all detected simultaneously, but without differentiation. While this approach often yields valuable and novel insights, the data represents only a fraction of the humoral immune response encoded in a serum sample. Each IgG subclass has distinct structural characteristics that influence function, and shifts in subclass abundance can reveal critical information about disease susceptibility, diagnosis, or prognosis. Similar functional and structural diversity exists across all antibody isotypes and subclasses, making detailed analysis essential for deeper immune profiling.

“We’re entering an exciting new phase in autoantibody research, where a more complete view of the immune response is finally within reach,” said Barney Saunders, PhD, CEO of CDI Labs. “In the past, autoantibody discovery and profiling has often been limited to pan-IgG analysis, but each isotype and subclass plays a distinct role in humoral immunity. Just as understanding the full spectrum of T cells is essential in studying cell-mediated immunity, capturing this diversity in antibodies is equally important. While earlier limitations in technology made this difficult, our new pan-isotype and subclass analysis capabilities now make it possible to explore these differences in far greater depth.”

New pan-isotype and subclass analysis services are available with the following CDI Labs platforms:

• HuProt™ services enable the analysis of binding to over 21,000 full-length, folded, GST-purified proteins, which represents over 80% of the human proteome. HuProt is the most comprehensive and thoroughly validated human protein arrays available.

• VirScan® services enable simultaneous epitope-level antibody profiling against most vertebrate viral proteomes using phage display immunoprecipitation sequencing (PhIP-Seq), which is a powerful method of multiplexed analysis that combines next-generation proteomics with high-throughput DNA sequencing.

About CDI Laboratories, Inc.

CDI Labs is a specialized CRO and lab services proteomics company. Powered by cutting-edge synthetic biology platforms, CDI Labs has generated the world’s largest collection of proteomes, and in doing so has built a team with deep proteomics bench expertise. CDI Labs offers unique services that enable customers to decipher and characterize molecular interactions across entire proteomes. Solutions span basic research, discovery, validation and clinical deployment phases, and include: autoantibody biomarker discovery and profiling; viral exposure profiling; immunogenicity assessment of cell, gene and radioligand therapies; antibody and ADC specificity profiling; target identification for monoclonals, biologics and drugs; and custom protein and monoclonal antibody manufacturing for downstream validation. To learn more about the latest services and technologies offered by CDI Labs, please visit our website at cdilabs.com.

HuProt and VirScan are a trademark and a registered trademark respectively, of CDI Laboratories, Inc. All other trademarks are the property of their respective owners. All products described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Media Contact

Chris Grimley

+1 415-425-8864

[email protected]